



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SERIAL NO. : 10/729,704
APPLICANTS : Guenzler-Pukall, et al.
FILING DATE : 04 December 2003
GROUP ART UNIT : 1654
EXAMINER : Roy R. Teller
DOCKET NO. : FP0602.1 US
TITLE : TREATMENT OF DIABETES

Commissioner for Patents
PO Box 1450
Alexandria VA 22313-1450

**NOTICE OF APPEAL FROM THE EXAMINER TO THE BOARD
OF PATENT APPEALS AND INTERFERENCES**

Sir:

Applicant hereby appeals to the Board of Patent Appeals and Interferences from the last decision of the Examiner in the Final Office Action dated 20 March 2008, in which claims 2, 5, 6, 8, 10, 12-31, and 34-36 were rejected, in the above-identified patent application.


The Commissioner is hereby authorized to charge any necessary fees to Deposit Account No. 50-0811, referencing Docket No. FP0602.1 US.

Please call Applicants' representative at 650.866.7289 with any questions regarding this communication or the above-identified application.

Respectfully submitted,

Date: 19 September 2008

By:


James E. Nesbitt, Ph.D.
Reg. No. 54,575

FibroGen, Inc.
225 Gateway Boulevard
South San Francisco, CA 94080
Main: 650.866.7200
Direct: 650.866.7289
Facsimile: 650.866.7292
jnesbitt@fibrogen.com

Certificate of mailing or transmission under 37 CFR § 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 19 September 2008.

Name: Michael Moores

Signature: 